Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has priced its underwritten public offering and concurrent private placement for gross proceeds to Lexeo of approximately $135 million, before deducting underwriting discounts and commissions and other expenses payable by Lexeo in connection with the transactions and excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares and pre-funded warrants are to be sold by Lexeo.

Lexeo offered 15,625,000 shares of its common stock in the public offering, at an offering price of $8.00 per share. In addition, Lexeo has granted the underwriters for the public offering a 30-day option to purchase up to an additional 2,343,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Concurrent with the public offering, Lexeo has agreed to sell pre-funded warrants to purchase 1,250,015 shares of common stock to Balyasny Asset Management at a price of $7.9999 per pre-funded warrant, in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, or the Securities Act, subject to the consummation of the public offering and other customary conditions. However, the consummation of the public offering is not contingent on the consummation of this concurrent private placement.

The public offering and concurrent private placement are expected to close on or about October 20, 2025, subject to satisfaction of customary closing conditions.

Leerink Partners, Cantor, Stifel and Oppenheimer & Co. are acting as joint book-running managers for the public offering. Baird is acting as lead manager for the public offering. Leerink Partners served as sole Placement Agent in connection with the concurrent private placement.

The public offering is being made pursuant to a Registration Statement on Form S-3, including a base prospectus, previously filed with, and declared effective by, the U.S. Securities and Exchange Commission (the “SEC”), and Lexeo has filed with the SEC a preliminary prospectus supplement and accompanying prospectus relating to the public offering. A final prospectus supplement and accompanying prospectus relating to the public offering will also be filed with the SEC. These documents can be accessed for free through the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the public offering may also be obtained from: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at [phone] ext. 6105, or by emailing [e-mail]; Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 E. 59th Street, 6th Floor, New York, New York 10022, or by email at [e-mail]; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at [phone] or by emailing [e-mail]; or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at [phone], or by email at [e-mail].